MERCK’S CLESROVIMAB (MK-1654), AN INVESTIGATIONAL RESPIRATORY SYNCYTIAL VIRUS (RSV) PREVENTATIVE MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCED INCIDENCE OF RSV DISEASE AND HOSPITALIZATION IN HEALTHY PRETERM AND FULL-TERM INFANTS

Reuters · 10/17 22:00

Please log in to view news